7.5.5. Treatment of Primary Immunoglobulin A Nephropathy
Restrictions:
Restricted to specialist use in adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.8 g/g*).
*equivalent to ≥90 mg/mmol
Restrictions:
Restricted to specialist use in adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g*).
*equivalent to ≥85 mg/mmol
Further restricted to patients whose condition has not responded adequately to current standard of care that is; maximally tolerated angiotensin converting enzyme inhibitor or angiotensin receptor blocker and sodium-glucose cotransporter-2 inhibitor, as appropriate. Patients should stop sparsentan at week 24 if no response to treatment.


